We are live on
!
Find out more
enGene Therapeutics Warrants
ENGNW
ENGNW
11 hedge funds and large institutions have $12.9M invested in enGene Therapeutics Warrants in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
2% more ownership
Funds ownership: 46.54% → 48.54% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less capital invested
Capital invested by funds: $13.9M → $12.9M (-$990K)
21% less funds holding
Funds holding: 14 → 11 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
11
Holders Change
-3
Holders Change %
-21.43%
% of All Funds
0.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
2
Reduced
1
Closed
5
Calls
$175K
Puts
–
Net Calls
+$175K
Net Calls Change
-$29K
Top Buyers
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$1.41M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$715K |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$487K |
| 4 |
ICM
Ionic Capital Management
New York
|
+$49.6K |
